In Vitro Pharmacology

Access Proof of Concept Tumor Cell Lines

Our clients have access to more than 300 validated tumor cell lines to direct clinical and regulatory strategy. As part of that preclinical collection of screening tools, you can:

Explore Drug Effects on Immune Cells

Assessing of the effects of your drug on antitumor immune cells can give earlier guidance on future immuno-oncology combination strategies.

Get Rapid, Accurate Compound Delivery

Our in-house Tecan D300 digital dispenser provides accurate and repeatable delivery of small and large molecules—and supports simple titrations to complex combination schemes.

Explore Our High-Risk Myeloma Cell Panel

For those engaged in multiple myeloma research, we provide access to highly predictive screening programs, including a diverse high-risk myeloma cell panel representing the major genomic alterations, now available for in vitro screening. We also hold commercial rights to the most predictive in vivo myeloma mouse model, the Vk*Myc model, to further explore the efficacy of new myeloma agents.

Ask us how you can get your preclinical plan started today.